|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bixel K and Hays JL: Olaparib in the
management of ovarian cancer. Pharmacogenomics Pers Med. 8:127–135.
2015. View Article : Google Scholar
|
|
3
|
Luvero D, Milani A and Ledermann JA:
Treatment options in recurrent ovarian cancer: Latest evidence and
clinical potential. Ther Adv Med Oncol. 6:229–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Narita T, Sasaoka S, Udagawa K, Ohyama T,
Wada N, Nishimatsu S, Takada S and Nohno T: Wnt10a is involved in
AER formation during chick limb development. Dev Dyn. 233:282–287.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sherwood V: WNT signaling: An emerging
mediator of cancer cell metabolism? Mol Cell Biol. 35:2–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu D, Zhao Y, Tawatao R, Cottam HB, Sen M,
Leoni LM, Kipps TJ, Corr M and Carson DA: Activation of the Wnt
signaling pathway in chronic lymphocytic leukemia. Proc Natl Acad
Sci USA. 101:pp. 3118–3123. 2004; View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hilliard TS, Gaisina IN, Muehlbauer AG,
Gaisin AM, Gallier F and Burdette JE: Glycogen synthase kinase 3β
inhibitors induce apoptosis in ovarian cancer cells and inhibit in
vivo tumor growth. Anticancer Drugs. 22:978–985. 2011.PubMed/NCBI
|
|
8
|
Arend RC, Londoño-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gatcliffe TA, Monk BJ, Planutis K and
Holcombe RF: Wnt signaling in ovarian tumorigenesis. Int J Gynecol
Cancer. 18:954–962. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu R, Zhai Y, Fearon ER and Cho KR:
Diverse mechanisms of beta-catenin deregulation in ovarian
endometrioid adenocarcinomas. Cancer Res. 61:8247–8255.
2001.PubMed/NCBI
|
|
11
|
Burkhalter RJ, Symowicz J, Hudson LG,
Gottardi CJ and Stack MS: Integrin regulation of beta-catenin
signaling in ovarian carcinoma. J Biol Chem. 286:23467–23475. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yoshioka S, King ML, Ran S, Okuda H,
MacLean JA II, McAsey ME, Sugino N, Brard L, Watabe K and Hayashi
K: WNT7A regulates tumor growth and progression in ovarian cancer
through the WNT/β-catenin pathway. Mol Cancer Res. 10:469–482.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen H, Wang Y and Xue F: Expression and
the clinical significance of Wnt10a and Wnt10b in endometrial
cancer are associated with the Wnt/β-catenin pathway. Oncol Rep.
29:507–514. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bonds J, Pollan-White S, Xiang L, Mues G
and D'Souza R: Is there a link between ovarian cancer and tooth
agenesis? Eur J Med Genet. 57:235–239. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kirikoshi H, Inoue S, Sekihara H and Katoh
M: Expression of WNT10A in human cancer. Int J Oncol. 19:997–1001.
2001.PubMed/NCBI
|
|
16
|
Long A, Giroux V, Whelan KA, Hamilton KE,
Tétreault MP, Tanaka K, Lee JS, Klein-Szanto AJ, Nakagawa H and
Rustgi AK: WNT10A promotes an invasive and self-renewing phenotype
in esophageal squamous cell carcinoma. Carcinogenesis. 36:598–606.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kirikoshi H, Sekihara H and Katoh M:
WNT10A and WNT6, clustered in human chromosome 2q35 region with
head-to-tail manner, are strongly coexpressed in SW480 cells.
Biochem Biophys Res Commun. 283:798–805. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hsu RJ, Ho JY, Cha TL, Yu DS, Wu CL, Huang
WP, Chu P, Chen YH, Chen JT and Yu CP: WNT10A plays an oncogenic
role in renal cell carcinoma by activating WNT/β-catenin pathway.
PLoS One. 7:e476492012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kirikoshi H, Sekihara H and Katoh M:
Up-regulation of WNT10A by tumor necrosis factor α and Helicobacter
pylori in gastric cancer. Int J Oncol. 19:533–536. 2001.PubMed/NCBI
|
|
20
|
Scully RE: World Health Organization
classification and nomenclature of ovarian cancer. Natl Cancer Inst
Monogr. 42:5–7. 1975.PubMed/NCBI
|
|
21
|
Shepherd JH: Revised FIGO staging for
gynaecological cancer. Br J Obstet Gynaecol. 96:889–892. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Denny L, Quinn M and Hacker N: FIGO cancer
report 2012. Int J Gynaecol Obstet. 119 Suppl 2:S892012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu J, Pan S, Hsieh MH, Ng N, Sun F, Wang
T, Kasibhatla S, Schuller AG, Li AG, Cheng D, et al: Targeting
Wnt-driven cancer through the inhibition of Porcupine by LGK974.
Proc Natl Acad Sci USA. 110:pp. 20224–20229. 2013; View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hanahan D and Weinberg RA: Hallmarks of
Cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Entschladen F, TL IV Drell, Lang K, Joseph
J and Zaenker KS: Tumour-cell migration, invasion, and metastasis:
Navigation by neurotransmitters. Lancet Oncol. 5:254–258. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Galbraith RL, Poole EM, Duggan D, Muehling
J, Hsu L, Makar K, Xiao L, Porter JD and Ulrich CM: Polymorphisms
in WNT6 and WNT10A and colorectal adenoma risk. Nutr Cancer.
63:558–564. 2011. View Article : Google Scholar : PubMed/NCBI
|
